The company’s implants are used in France and the United States, in addition to 14 other countries, and are the subject of nine papers on clinical and medico-economic value. The company launched the JAZZ Band less than three years ago, with more than 2,000 surgeries accounting for the 10,000 implantations.
“We do not intend to stop here, and will intensify our efforts to rapidly obtain additional clearances in major markets while providing important new clinical data and continuing to deploy the best possible technologies to meet surgeon demands,” said CEO Ludovic Lastennet.
Earlier this year, Implanet achieved FDA clearance to market the JAZZ Band as usable with other posterior thoraco-lumbar fixation systems. Previously the platform was only used with the Implanet SpineSystem.
More articles on orthopedic devices:
Xtant Medical to participate in NASS meeting: 5 things to know
Nexxt Spine’s manufacturing process aids company growth: 5 key points
NuVasive’s cervical corpectomy cage receives FDA clearance
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
